Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial

@article{Wu2020EfficacyAS,
  title={Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial},
  author={Xiaoke Wu and Kaijiang Yu and Yongchen Wang and Wanhai Xu and Hongli Ma and Yan Hou and Yue Li and Benzhi Cai and Liying Zhu and Min Zhang and Xiaoli Hu and Jingshu Gao and Yu Wang and Huichao Qin and Wenjie Wang and Mingyan Zhao and Xia Wu and Yong Zhang and Lu Li and Kang Li and Zhimin Du and Ben Willem J. Mol and Baofeng Yang},
  journal={Engineering (Beijing, China)},
  year={2020},
  volume={6},
  pages={1185 - 1191}
}
  • Xiaoke Wu, Kaijiang Yu, +20 authors Baofeng Yang
  • Published 2020
  • Medicine
  • Engineering (Beijing, China)
No therapeutics have been proven effective yet for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To assess the efficacy and safety of Triazavirin therapy for COVID-19, we conducted a randomized, double-blinded controlled trial involving hospitalized adult patients with COVID-19. Participants were enrolled from ten sites, and were randomized into two arms of the study with a ratio of 1:1. Patients were treated with… Expand

Figures and Tables from this paper

Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis
TLDR
The available evidence does not support the use of any antiviral drugs for COVID-19, and lopinavir (400mg)/ritonavir (100mg) significantly increased diarrhea, nausea and vomiting compared with placebo/no treatment and other antivirals, and was ranked worst for these outcomes. Expand
Current evidence for COVID-19 therapies: a systematic literature review
TLDR
The need for well-designed clinical trials of therapeutic interventions for COVID-19 to increase the quality of available evidence and the importance of tailoring interventions to disease stage and severity for maximum efficacy is emphasised. Expand
Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19
TLDR
Yearly administration of riamilovir as opposed to the umifenovir and ribavirin in therapy of moderate SARS-CoV-2 infection was associated with significant shorter time to clinical improvement by 14 day of hospitalization. Expand
Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications
TLDR
There is currently no single worldwide approved therapeutic option for patients with COVID-19 despite the initial hype with medicines, including hydroxychloroquine, Nonetheless, dexamethasone has shown promise in symptomatic treatment and convalescent plasma in boosting immunity. Expand
Current evidence for COVID-19 therapies: a systematic literature review
TLDR
The need for well-designed clinical trials of therapeutic interventions for COVID-19 to increase the quality of available evidence is highlighted and the importance of tailoring interventions to disease stage and severity for maximum efficacy is emphasised. Expand
CLINICAL TRIALS IN COVID-19 MANAGEMENT & PREVENTION: A META-EPIDEMIOLOGICAL STUDY EXAMINING METHODOLOGICAL QUALITY
TLDR
The characteristics of randomized clinical trials investigating prophylaxis or treatment of Covid-19 infection are described and the effect of trial characteristics on whether the study reported a statistically significant effect on the primary outcome(s) is examined. Expand
Experience of the preventive use of the drug Riamilovir in the foci of coronavirus infection (COVID-19)
  • Medicine
  • Terapevticheskii arkhiv
  • 2021
TLDR
The effectiveness and safety of the preventive use of the drug Riamilovir allow to recommend it for emergency drug prophylaxis in contact persons in the foci of a new coronavirus infection (COVID-19). Expand
The Efficacy and Safety of Riamilovir in the Treatment of Patients with COVID-19
TLDR
The results of the study on the e-cacy, safety, and tolerability of Riamilovir allow it as a means of etiotropic therapy of the new coronavirus infection (COVID-19) to be recommended. Expand
Drug treatments for covid-19: living systematic review and network meta-analysis
TLDR
Glucocorticoids probably reduce mortality and mechanical ventilation in patients with covid-19 compared with standard care and the effectiveness of most interventions is uncertain because most of the randomised controlled trials so far have been small and have important study limitations. Expand
Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials
TLDR
There was no therapeutic agent that consistently resulted in positive outcomes across SARS, MERS, and COVID-19 and further RCTs are required. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 18 REFERENCES
The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol
TLDR
This study is being conducted at ten study sites in Heilongjiang Province, China, to investigate the efficacy and safety of Triazavirin (TZV) versus its placebo in COVID-19 patients. Expand
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
TLDR
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit. Expand
Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.
TLDR
Despite much resistance and controversy regarding asking patients with EVD to participate in a randomized clinical trial (RCT), the National Institutes of Health conducted the first and only RCT during that outbreak; however, it was too late for the RCT to be completed. Expand
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)
  • Medicine
  • Chinese medical journal
  • 2020
TLDR
The Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) is revised to further strengthen the early diagnosis and early treatment of the disease, improve the cure rate, reduce the mortality rate, avoid nosocomial infection as much as possible and pay attention to the spread caused by the imported cases from overseas. Expand
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).
TLDR
This case report describes an otherwise healthy 53-year-old woman who tested positive for CO VID-19 and was admitted to the cardiac care unit in March 2020 for acute myopericarditis with systolic dysfunction, confirmed on cardiac magnetic resonance imaging, the week after onset of fever and dry cough due to COVID-19. Expand
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
TLDR
The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported. Expand
[A new antiviral drug Triazavirin: results of phase II clinical trial].
TLDR
The treatment with oral Triazavirin significantly reduced the duration of the main clinical symptoms of influenza, decreased the incidence of the influenza-related complications and the use of symptomatic drugs. Expand
[Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice].
TLDR
In high doses (200-400 mg/kg) Triazavirin moderately protected the infected animals, and a significant increase of the animal lifespan and a statistically valid decrease of the virus accumulation in the target organ (the brain) were observed. Expand
Antiviral Properties, Metabolism, and Pharmacokinetics of a Novel Azolo-1,2,4-Triazine-Derived Inhibitor of Influenza A and B Virus Replication
TLDR
TZV suppressed the replication of influenza virus in cell culture and in chicken chorioallantoic membranes, and it protected mice from death caused by type A and B influenza viruses, and TZV was also effective against a rimantadine-resistant influenza virus strain and against avian influenza A virus H5N1 strains. Expand
...
1
2
...